CASI 10-Q Quarterly Report Sept. 30, 2013 | Alphaminr
CASI Pharmaceuticals, Inc.
ALPHAMINR

CASI 10-Q Quarter ended Sept. 30, 2013

Balance Sheet
Cash Flow
Income Statement
CASI PHARMACEUTICALS, INC.
10-Ks,20-Fs and 10-Qs
20-F
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-Q
Quarter ended June 30, 2012
10-Q
Quarter ended March 31, 2012
10-K
Fiscal year ended Dec. 31, 2011
10-Q
Quarter ended Sept. 30, 2011
10-Q
Quarter ended June 30, 2011
10-Q
Quarter ended March 31, 2011
10-K
Fiscal year ended Dec. 31, 2010
10-Q
Quarter ended Sept. 30, 2010
10-Q
Quarter ended June 30, 2010
10-Q
Quarter ended March 31, 2010
10-K
Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
Filed on Feb. 14, 2023
DEF 14A
Filed on April 15, 2022
DEF 14A
Filed on May 10, 2021
DEF 14A
Filed on April 22, 2020
DEF 14A
Filed on April 30, 2019
DEF 14A
Filed on April 17, 2018
DEF 14A
Filed on April 14, 2017
DEF 14A
Filed on April 8, 2016
DEF 14A
Filed on April 17, 2015
DEF 14A
Filed on Oct. 17, 2014
DEF 14A
Filed on April 21, 2014
DEF 14A
Filed on April 16, 2013
DEF 14A
Filed on March 22, 2012
DEF 14A
Filed on April 28, 2011
DEF 14A
Filed on April 29, 2010
10-Q 1 v359054_10q.htm FORM 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2013
¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to _____________.
Commission file number 0-20713
ENTREMED, INC .
(Exact name of registrant as specified in its charter)
Delaware
58-1959440
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
9620 Medical Center Drive, Suite 300
Rockville, Maryland
(Address of principal executive offices)
20850
(Zip code)
(240) 864-2600
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YES x NO ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES x NO ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer ¨
Smaller reporting
company þ
Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ¨ NO x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the most recent practicable date.
Class
Outstanding at November 8, 2013
Common Stock $.01 Par Value
27,040,429
ENTREMED, INC.
Table of Contents
PAGE
PART I. FINANCIAL INFORMATION
Item 1 — Consolidated Financial Statements
Consolidated Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012
4
Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2013 and 2012 (unaudited)
5
Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2013 and 2012 (unaudited)
6
Notes to Consolidated Financial Statements (unaudited)
7
Item 2 — Management’s Discussion and Analysis of Financial Condition and Results of Operations
12
Item 3 — Quantitative and Qualitative Disclosures About Market Risk
21
Item 4 — Controls and Procedures
21
Part II. OTHER INFORMATION
Item 1 — Legal Proceedings
22
Item 1A – Risk Factors
22
Item 2 — Unregistered Sales of Equity Securities and Use of Proceeds
22
Item 3 — Defaults upon Senior Securities
22
Item 4 — Removed and Reserved
22
Item 5 — Other Information
22
Item 6 — Exhibits
22
SIGNATURES
23
2

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report contains certain forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements also may be included in other statements that we make. All statements that are not descriptions of historical facts are forward-looking statements. These statements can generally be identified by the use of forward-looking terminology such as “believes,” “expects,” “intends,” “may,” “will,” “should,” or “anticipates” or similar terminology. These forward-looking statements include, among others, statements regarding the timing of our clinical trials, our cash position and future expenses, and our future revenues.
Our forward-looking statements are based on information available to us today, and we will not update these statements.
Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid ® resulting in reduced or no royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov .
3

PART I. FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
EntreMed, Inc.
Consolidated Balance Sheets
(Unaudited)
September 30, 2013
December 31, 2012
(Unaudited)
(Note 1)
ASSETS
Current assets:
Cash and cash equivalents
$
15,871,694
$
8,049,237
Accounts receivable, net of allowance for doubtful accounts of $12,536
at September 30, 2013 and December 31, 2012
-
669,310
Prepaid expenses and other
316,054
189,465
Total current assets
16,187,748
8,908,012
Property and equipment, net
56,582
52,556
Other assets
17,965
17,427
Total assets
$
16,262,295
$
8,977,995
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
352,250
$
504,851
Payable to related party
-
86,683
Accrued liabilities
149,152
151,219
Total current liabilities
501,402
742,753
Commitments and contingencies
-
-
Stockholders' equity :
Convertible preferred stock, $1.00 par value;
5,000,000 shares authorized and 0 shares issued and
outstanding at September 30, 2013 and December 31, 2012
-
-
Common stock, $.01 par value:
170,000,000 shares authorized at September 30, 2013 and December 31,
2012; 27,119,974 and 22,582,938 shares issued at September 30, 2013
and December 31, 2012, respectively
271,200
225,828
Additional paid-in capital
421,285,077
409,374,905
Treasury stock, at cost: 79,545 shares held at September 30, 2013 and
December 31, 2012
(8,034,244)
(8,034,244)
Accumulated deficit
(397,761,140)
(393,331,247)
Total stockholders' equity
15,760,893
8,235,242
Total liabilities and stockholders' equity
$
16,262,295
$
8,977,995
See accompanying notes.
4

EntreMed, Inc.
Consolidated Statements of Operations
(Unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 30,
September 30,
September 30,
2013
2012
2013
2012
Revenues:
Royalties
$
-
$
-
$
-
$
-
Costs and expenses:
Research and development
793,839
623,092
2,136,796
1,880,629
General and administrative
648,735
564,626
2,294,338
2,262,874
1,442,574
1,187,718
4,431,134
4,143,503
Interest (income) expense
(408)
-
(1,241)
10,041,292
Net loss
(1,442,166)
(1,187,718)
(4,429,893)
(14,184,795)
Dividends on Series A convertible preferred stock
-
-
-
(335,000)
Net loss attributable to common shareholders
$
(1,442,166)
$
(1,187,718)
$
(4,429,893)
$
(14,519,795)
Net loss per share (basic and diluted)
$
(0.05)
$
(0.05)
$
(0.17)
$
(0.81)
Weighted average number of common shares
outstanding (basic and diluted)
27,031,734
22,503,393
25,817,642
17,897,231
See accompanying notes.
5

EntreMed, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
2013
2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
$
(4,429,893)
$
(14,184,795)
Adjustments to reconcile net loss to net cash used in operating
activities:
Depreciation and amortization
12,900
15,117
Stock-based compensation expense
1,554,422
746,104
Non-cash interest
-
10,041,292
Changes in operating assets and liabilities:
Accounts receivable
669,310
1,932,742
Prepaid expenses and other
(127,127)
(58,383)
Accounts payable
(152,601)
31,197
Payable to related party
(86,683)
55,685
Accrued liabilities
(2,067)
(64,827)
Net cash used in operating activities
(2,561,739)
(1,485,868)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of furniture and equipment
(16,926)
(11,818)
Net cash used in investing activities
(16,926)
(11,818)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible notes and warrants
-
10,000,000
Debt issuance costs
-
(683,955)
Stock issuance costs
(448,402)
(88,855)
Net proceeds from sale of common stock or exercise of options and warrants
10,849,524
1,999
Net cash provided by financing activities
10,401,122
9,229,189
Net increase in cash and cash equivalents
7,822,457
7,731,503
Cash and cash equivalents at beginning of period
8,049,237
1,080,630
Cash and cash equivalents at end of period
$
15,871,694
$
8,812,133
Supplemental disclosure of cash flow information:
Non-cash financing activities:
Common stock issued in connection with conversion of convertible notes
and accrued interest
$
-
$
10,144,658
Common stock issued in connection with conversion of preferred stock
$
-
$
3,500,000
Warrant issued to placement agent
$
115,150
$
-
See accompanying notes.
6

ENTREMED, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2013 (unaudited)
1.
Basis of Presentation
The accompanying consolidated financial statements include the accounts of EntreMed, Inc. and its subsidiaries (“EntreMed” or “the Company”), Miikana Therapeutics, Inc. (“Miikana”) and EntreMed (Beijing) Co., Ltd. (“EntreMed China”). EntreMed China is a non-stock Chinese entity with 100 % of its interest owned by EntreMed. EntreMed China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has entered into a lease for operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.
The accompanying unaudited consolidated financial statements have been prepared in accordance with U. S. generally accepted accounting principles for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, such consolidated financial statements do not include all of the information and disclosures required by U. S. generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying December 31, 2012 financial information was derived from our audited financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012. Operating results for the three and nine-month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. For further information, refer to our audited consolidated financial statements and footnotes thereto included in our Form 10-K for the year ended December 31, 2012.
Material subsequent events have been considered for disclosure and recognition through the filing date of these consolidated financial statements.
Liquidity Risks and Management’s Plans
Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $ 397.8 million.  The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In February 2012 (the “2012 Financing”), the Company received the proceeds from a $ 10 million convertible note financing. Upon approval by the Company’s stockholders at the 2012 annual stockholders meeting, the convertible notes automatically converted into common stock on May 1, 2012 (see Note 3). In addition, on March 14, 2013 (the “2013 Financing”), the Company closed on the sale of 4,495,828 shares of common stock and 2,247,912 warrants to certain investors for approximately $ 10.8 million (see Note 3). As a result of these transactions, along with on-going cost containment measures, the Company has sufficient resources to fund its operations for at least the next twelve months. The Company will continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive arrangements in China to support the Company’s dual-country approach to drug development.
7

2.
Related Party Transaction
On October 31, 2012, EntreMed China obtained the necessary local regulatory approvals to establish a bank account in Beijing. Prior to establishing a bank account, EntreMed China incurred certain startup and initial operating expenses, which were advanced by the Company’s Chief Executive Officer on behalf of EntreMed China, totaling $ 86,683 . The full amount was repaid to the Company’s Chief Executive Officer in February 2013.
In connection with the successful completion of the 2012 Financing, and prior to his appointment to the Board of Directors, the Company paid a 6% advisory fee to Emerging Technology Partners LLC, of which the Company’s Chairman is a general partner, for due diligence, its role in structuring and negotiating the transaction and as reimbursement for fees incurred. The 2012 Financing was approved by stockholders at the 2012 annual meeting.

3.
Stockholders’ Equity
In connection with the 2012 Financing, and upon stockholder approval of the 2012 Financing at the 2012 annual meeting on April 30, 2012, Celgene Corporation (“Celgene”) converted all of its preferred stock to an aggregate of 1,522,727 shares of common stock, pursuant to the terms and conditions of the Series A Preferred Stock. As a result, as of May 1, 2012, there is no Series A Preferred Stock or any class of preferred stock outstanding. In connection with the stockholder approval of the 2012 Financing, Celgene waived all accrued dividends on the Series A Preferred Stock, and Celgene is no longer entitled to any liquidation preference on its shares.
2013 Financing
As described in Note 1 and in connection with the 2013 Financing, on March 1, 2013, the Company entered into a definitive agreement with certain investors (collectively, the “2013 Investors”) for a financing in the aggregate amount of approximately $ 10.8 million. In connection with the 2013 Financing, the Company entered into a Securities Purchase Agreement with the 2013 Investors pursuant to which the Company agreed to sell in a transaction registered under the Securities Act of 1933, as amended, 4,495,828 shares of the Company’s common stock and warrants to purchase up to an aggregate of 2,247,912 shares of common stock (the “2013 Investor Warrants”).  The 2013 Investor Warrants cover a number of shares of common stock equal to 50% of the number of shares purchased by each Investor. The 2013 Investor Warrants have an exercise price of $ 2.91 per share and became exercisable on September 4, 2013 and expire on September 4, 2016. The fair value of the 2013 Warrants issued is $ 3,574,180 , calculated using the Black-Scholes-Merton valuation model value of $ 1.59 with an expected and contractual life of 3.5 years, an assumed volatility of 102.3 %, and a risk-free interest rate of 0.40 %. The Company completed the closings on the 2013 Financing on March 14, 2013 and received net proceeds of approximately $ 10.3 million.
In connection with the 2013 Financing, the Company also issued a warrant to its placement agent to purchase up to 61,250 shares of common stock at an exercise price of $ 3.00 per share of common stock (the “Agent’s Warrant”). The Agent’s Warrant became exercisable on September 4, 2013 and will expire on October 9, 2017 . The fair value of the Agent’s Warrant issued is $ 115,150 , calculated using the Black-Scholes-Merton valuation model value of $ 1.88 with an expected and contractual life of 4.6 years, an assumed volatility of 111.9 %, and a risk-free interest rate of 0.85 %.
8

2012 Financing
As described in Note 1 and in connection with the 2012 Financing, on January 20, 2012, the Company entered into a Convertible Note and Warrant Purchase Agreement (the “Purchase Agreement”) with certain strategic accredited investors (the “Investors”), pursuant to which the Company issued and sold to the Investors, in a private placement, subordinated mandatorily convertible promissory notes (collectively, the “Notes”) with an aggregate principal amount of $ 10 million. The Company also issued warrants (the “2012 Warrants”) to the Investors to purchase an aggregate of 1,739,132 shares of the Company's common stock, par value $ 0.01 per share (“Common Stock”). The 2012 Warrants cover a number of shares of common stock equal to 20% of the principal amount of the Notes purchased by each Investor, divided by $1.15. The 2012 Warrants have an exercise price of $1.40 per share and shall be exercisable on or after July 29, 2012 and expire five years after the exercisable date. The relative fair value of the 2012 Warrants issued is $ 2,155,527 , calculated using the Black-Scholes-Merton valuation model value of $ 1.58 with an expected and contractual life of 5.5 years, an assumed volatility of 103 %, and a risk-free interest rate of 0.71 %. The 2012 Warrants were recorded as additional paid-in-capital and a discount on the Notes of $ 2,155,527 was fully amortized as non-cash interest expense during the year ended December 31, 2012 as a result of the conversion of the Notes.
The 2012 Financing was completed on February 2, 2012. The Company received net proceeds of approximately $ 9.3 million. The Company paid one of the investors, in a related-party transaction, a fee in the amount of 6 % of the aggregate amount raised in the 2012 Financing. In connection with the 2012 Financing, the Company incurred a total of $ 683,955 of debt issuance costs. All debt issuance costs were fully amortized and recorded as interest expense upon conversion of the Notes in the second quarter of 2012.
The Company received approval of the 2012 Financing from the Company's stockholders at the 2012 annual stockholders meeting held on April 30, 2012. On May 1, 2012, the Notes, including accrued interest of $ 144,658 , automatically and immediately converted into 8,821,431 shares of common stock and the 2012 Warrants became exercisable as of July 29, 2012. The Notes bore an interest rate of 6 % and converted at a conversion price of $ 1.15 per share. The conversion price reflected the 10-day average closing sale price of the Company’s Common Stock ended on January 20, 2012.
The Notes were not convertible, and the Warrants were not exercisable, prior to receiving stockholder approval. The Notes contained a contingent beneficial conversion feature as the conversion price of the shares was less than the share price on the date of the Notes issuance. The beneficial conversion feature was valued at $ 7,057,153 and was recorded as non-cash interest expense and additional paid-in-capital in the second quarter of 2012, upon removal of the contingency and conversion of the Notes on May 1, 2012.

4.
Share-Based Compensation
The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In May 2013, the Company’s shareholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares reserved for issuance from 1,730,000 to 4,230,000 shares of common stock to be available for grants and awards. As of September 30, 2013, there are 3,491,229 shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $ 1.75 to $ 60.39 . In 2012, the Company awarded options to two officers, a portion of which is subject to certain performance conditions and market conditions. Options granted under the plans generally vest over periods varying from immediately to three years, are not transferable and generally expire ten years from the date of grant. As of September 30, 2013, 1,210,876 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan.
9

The Company records compensation expense associated with stock options and other equity-based compensation in accordance with provisions of authoritative guidance. Compensation costs are recognized based on a straight-line method over the requisite service period, which is generally the option vesting term of up to three years. Awards with performance conditions will be expensed if it is probable that the performance condition will be achieved. As of September 30, 2013, no expense has been recorded for share awards with performance conditions.
The Company’s net loss for the nine months ended September 30, 2013 and 2012 includes compensation expense of $ 1,554,422 and $ 746,104 , respectively, related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:
NINE MONTH PERIOD ENDED
SEPTEMBER 30,
2013
2012
Research and development
$
587,186
$
186,003
General and administrative
967,236
560,101
Share-based compensation expense
$
1,554,422
$
746,104
Net share-based compensation expense, per common share:
Basic and diluted
$
0.06
$
0.04
The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of stock options granted to employees. Option valuation models, including Black-Scholes-Merton, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award.
Following are the weighted-average assumptions used in valuing the stock options granted during the nine-month periods ended September 30, 2013 and 2012:
NINE MONTH PERIOD ENDED
SEPTEMBER 30,
2013
2012
Expected volatility
105.37
%
101.67
%
Risk-free interest rate
1.01
%
0.94
%
Expected term of option
5.76 years
5.74 years
Forfeiture rate*
5.00
%
5.00
%
Expected dividend yield
0.00
%
0.00
%
* - Authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. During the nine- month periods ended September 30, 2013 and 2012, forfeitures were estimated at 5 %.
10

The weighted average fair value of stock options granted during the nine-month periods ended September 30, 2013 and 2012 was $ 1.43 and $ 2.04 , respectively.
A summary of the Company’s stock option plans and of changes in options outstanding under the plans for the nine months ended September 30, 2013 is as follows:
Weighted
Average
Number of
Exercise
Options
Price
Outstanding at January 1, 2013
1,636,544
$
5.07
Granted
1,934,500
$
1.79
Exercised
(3,817)
$
1.88
Expired
(75,998)
$
25.43
Forfeited
-
$
-
Outstanding at September 30, 2013
3,491,229
$
2.79
Vested and expected to vest at September 30, 2013
3,408,628
$
2.81
Exercisable at September 30, 2013
1,839,219
$
3.62
Cash received from option exercises under all share-based payment arrangements for the three and nine months ended September 30, 2013 was $ 0 and $ 7,190 , respectively. Cash received from option exercises for the three and nine months ended September 30, 2012 was $ 0 and $ 1,999 , respectively.

5. Income Taxes
At December 31, 2012, the Company had a $ 3.0 million unrecognized tax benefit. The Company recorded a full valuation allowance on the net deferred tax asset recognized in the consolidated financial statements as of December 31, 2012.
During the nine months ended September 30, 2013, there were no material changes to the measurement of unrecognized tax benefits in various taxing jurisdictions. The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense.
The tax returns for all years in the Company’s major tax jurisdictions are not settled as of January 1, 2013; no changes in settled tax years have occurred through September 30, 2013. Due to the existence of tax attribute carryforwards (which are currently offset by a full valuation allowance), the Company treats all years’ tax positions as unsettled due to the taxing authorities’ ability to modify these attributes.
11

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
OVERVIEW
We are a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market. In 2012, we refocused our clinical and regulatory strategy to leverage resources and opportunities in China and are currently conducting activities in both China and United States in order to accelerate delivery of clinical data and to reduce costs of clinical trials. Our lead drug candidate is ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which we will continue to develop under the FDA, and will include clinical sites in China, and in parallel will develop locally under the China Food and Drug Administration (CFDA). Our market focus includes developed countries, and also in particular, China, which has a pharmaceutical products market that we believe will continue to grow rapidly. Through partnerships, collaborations, and strategic acquisitions, we intend to add additional drug candidates to our pipeline for development using our US and China strategy. We intend to employ a market-oriented approach to identify pharmaceutical candidates that we believe have the potential for gaining widespread market acceptance either globally or in China and for which development can be accelerated under our US and China drug development strategy.
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 exerts its effects through multiple mechanisms of action, including anti-proliferative activity and the inhibition of angiogenesis. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3, and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has demonstrated significant, dose-dependent preclinical activity as a single agent, including tumor regression, in multiple xenograft models (e.g. breast, colon, leukemia), as well as activity towards ex vivo-treated human leukemia patient cells. ENMD-2076 also has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma, and in a Phase 2 trial for ovarian cancer.
Clinical Phase 1 results were published (Clin Cancer Res 2011;17:849-860) and data from the leukemia and myeloma studies were presented during the American Society of Hematology meeting in December 2010. Anti-cancer activity was demonstrated with ENMD-2076 treatment in a variety of solid and hematological cancer patients. Also, as previously reported, at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2011, Phase 2 data in ovarian cancer patients was presented by the principal investigator conducting the Phase 2 ENMD-2076 study. The data demonstrated ENMD-2076 activity in a population of difficult to treat platinum resistant patients. In October 2011, we announced that the final data for the primary endpoint of progression free survival rate at 6 months was 22 percent. Phase 2 data in ovarian cancer were also published in the European Journal of Cancer in September 2012 in an article entitled “ENMD-2076, an Oral Inhibitor of Angiogenic and Proliferation Kinases, Has Activity in Recurrent, Platinum Resistant Ovarian Cancer.” We believe that the data, together with the Phase 1 results, provide support for additional clinical studies in ovarian cancer and other forms of cancer. We continue to monitor patients who are receiving ENMD-2076, and are focused on collecting additional data on overall survival and other endpoints.
12

In November 2012, results of a preclinical study in triple-negative breast cancer (TNBC) of ENMD-2076 were published in the article, entitled “Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models”. Through this study, ENMD-2076 shows activity against preclinical models of breast cancer with more robust activity against TNBC. The study also supports further clinical investigation of ENMD-2076 in patients with metastatic TNBC with an emphasis on the continued development of p53-based predictive biomarkers. It provides strong support for the rational of our ongoing Phase 2 TNBC trial.
In December 2012, to advance our global development strategy, we submitted a new drug clinical trial application with the CFDA to conduct global clinical trials in triple-negative breast cancer patients using our proprietary drug candidate, ENMD-2076. CFDA has accepted of our application package and we are working with the CFDA to move the process forward towards approval. CFDA’s approval of our application would allow us to conduct clinical trials in China and supplement our ongoing Phase 2 triple-negative breast cancer trial currently underway at the University of Colorado and Indiana University.
In June 2013, we submitted a new drug global clinical trial application with the CFDA to expand our Phase 2 clinical trial of ENMD-2076 in advanced/metastatic sarcoma which currently is being conducted at Princess Margaret Hospital.
In July 2013, we initiated a crossover bioavailability and food effect study of ENMD-2076. The study is a single-blind, randomized, single-dose, crossover study with a food effect arm to investigate the safety and relative bioavailability of two dosage forms of ENMD-2076 administered as escalating doses in two cohorts of healthy subjects. The study is expected to enroll approximately 29 healthy adult volunteers and will be conducted in Tempe, Arizona by a clinical research organization. We anticipate the clinical portion of the study will be completed by year end, and that pharmacokinetic analysis will be completed in early 2014.
In October 2013, we commenced a multi-center Phase 2 study of Oral ENMD-2076 administered to patients with Ovarian Clear Cell Carcinomas (OCCC). The study is led by principal investigator Amit Oza, MD at Princess Margaret Cancer Centre in Toronto, Canada with participation of up to seven additional cancer centers in Canada and the United States.
ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia (“AML”).
ENMD-2076 is our only program currently under active clinical evaluation. Our other product candidates in the pipeline include 2-methoxyestrdiol (2ME2) for autoimmune diseases for which we have an approved IND in rheumatoid arthritis treatment, and MKC-1, programs for which we own or have exclusive licenses.
We intend to advance clinical development of ENMD-2076 and the implementation of our plans will include leveraging our resources in both the United States and China. In order to capitalize on the drug development and capital resources available in China, the Company is doing business in China through its wholly-owned Chinese subsidiary that will execute the China portion of the Company’s drug development strategy, including conducting clinical trials in China, pursuing local funding opportunities and strategic collaborations, and implementing the Company’s plan for accelerated development and commercialization in the China market.
13

Since inception, we have incurred significant losses from operations and have incurred an accumulated deficit of $397.8 million.  We expect to continue to incur operating losses for the foreseeable future due to, among other factors, our continuing clinical activities. Based on current plans, due in large part to the $10.8 million proceeds from our 2013 Financing and the $10 million proceeds from our 2012 Financing, we expect our current available cash and cash equivalents to meet our cash requirements for at least the next twelve months. We will continue to exercise tight controls over operating expenditures. In developing drug candidates, we intend to use and leverage resources available to us in both the United States and China. We intend to pursue additional equity financing opportunities as well as opportunities to raise capital through forms of non- or less- dilutive arrangements, such as partnerships and collaborations with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our product candidate that we intend to pursue to commercialization. However, there can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all.
CRITICAL ACCOUNTING POLICIES AND THE USE OF ESTIMATES
The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Our critical accounting policies, including the items in our financial statements requiring significant estimates and judgments, are as follows:
-
Revenue Recognition - We recognize revenue in accordance with the provisions of authoritative guidance issued, whereby revenue is not recognized until it is realized or realizable and earned. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed and determinable and collectibility is reasonably assured.
-
Royalty Revenue – Royalties from licenses are based on third-party sales and recorded as earned in accordance with contract terms, when third-party results are reliably measured and collectibility is reasonably assured. In 2004, certain provisions of a purchase agreement dated June 14, 2001 by and between Bioventure Investments kft (“Bioventure”) and the Company were satisfied and, as a result, beginning in 2005 we became entitled to share in the royalty payments received by Royalty Pharma Finance Trust, successor to Bioventure, on annual Thalomid ® sales above a certain threshold. Based on the licensing agreement royalty formula, annual royalty sharing commences when net royalties received by Royalty Pharma exceeds $15,375,000. We do not expect to meet the threshold to earn any revenue from royalties on the sale of Thalomid ® in 2013 or in any subsequent year.
14

-
We are also eligible to receive royalties from Oxford Biomedica, PLC based on a portion of the net sales of products developed for the treatment of ophthalmic (eye) diseases based in part on the Endostatin gene. We did not receive any payment from Oxford Biomedica, PLC in 2012 and do not expect to receive payments from Oxford Biomedica, PLC in 2013.
-
Royalty payments, if any, are recorded as revenue when received and/or when collectibility is reasonably assured.
-
Research and Development - Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Research and development costs are expensed as incurred.
-
Expenses for Clinical Trials – Expenses for clinical trials are incurred from planning through patient enrollment to reporting of the data. We estimate expenses incurred for clinical trials that are in process based on patient enrollment and based on clinical data collection and management. Costs that are associated with patient enrollment are recognized as each patient in the clinical trial completes the enrollment process. Estimated clinical trial costs related to enrollment can vary based on numerous factors, including expected number of patients in trials, the number of patients that do not complete participation in a trial, and when a patient drops out of a trial. Costs that are based on clinical data collection and management are recognized in the reporting period in which services are provided. In the event of early termination of a clinical trial, we would accrue an amount based on estimates of the remaining non-cancelable obligations associated with winding down the clinical trial.
-
Stock-Based Compensation – All share-based payment transactions are recognized in the financial statements at their fair values. Compensation expense associated with service, performance, market condition based stock options and other equity-based compensation is recorded in accordance with provisions of authoritative guidance. The fair value of awards whose fair values are calculated using the Black-Scholes option pricing model is generally being amortized on a straight-line basis over the requisite service period and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. The fair value of awards with market conditions, which are valued using a binomial model, is being amortized based upon the estimated derived service period. Share-based awards granted to employees with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Such an award with a performance condition will be expensed if it is probable that a performance condition will be achieved. As of September 30, 2013, no expense has been recorded for share awards with performance conditions. Using the straight-line expense attribution method over the requisite service period, which is generally the option vesting term of one to three years, share-based compensation expense recognized for the nine months ended September 30, 2013 and 2012 totaled approximately $1,554,000 and $746,000, respectively.
The determination of fair value of stock-based payment awards on the date of grant using the Black-Scholes or binomial model is affected by our stock price, as well as the input of other subjective assumptions. These assumptions include, but are not limited to, the expected forfeiture rate and expected term of stock options and our expected stock price volatility over the term of the awards. Changes in the assumptions can materially affect the fair value estimates.
15

Any future changes to our share-based compensation strategy or programs would likely affect the amount of compensation expense recognized.
RESULTS OF OPERATIONS
For the Three and Nine Months Ended September 30, 2013 and September 30, 2012.
Revenues . There were no revenues recorded during the three and nine months ended September 30, 2013 or September 30, 2012. Based on the recent trend, we expect annual sales of Thalomid ® in 2013 to continue to decrease to a level below the threshold amount to trigger a royalty payment to the Company. As a result we do not expect to earn any royalty revenue in 2013 or in any subsequent year. We become entitled to share in the royalty payments received by Royalty Pharma Finance Trust on annual Thalomid ® sales when Royalty Pharma Finance Trust receives more than $15,375,000 in royalties, pursuant to a 2001 agreement with Royalty Pharma. Thalomid ® is distributed and sold by Celgene Corporation and/or its affiliates, and thus, we have no control over sales of Thalomid ® or the amount, if any, of royalty payments we will receive.
Research and Development Expenses. Our research and development expenses for the three and nine months ended September 30, 2013 totaled approximately $794,000 and $2,137,000, respectively. Research and development expenses for the corresponding 2012 periods were approximately $623,000 and $1,881,000, respectively. Reflected in our Research and Development expenses totaling $794,000 for the three-month period ended September 30, 2013 are direct project costs of $532,000 for ENMD-2076 and $11,000 for 2ME2. The 2012 research and development expenses for the comparable period included $378,000 for ENMD-2076 and $63,000 for 2ME2. Research and development expenses totaling $2,137,000 for the nine-month period ended September 30, 2013 include direct project costs of $1,185,000 related to ENMD-2076 and $45,000 related to 2ME2. The 2012 research and development expenses for the comparable period included $1,008,000 for ENMD-2076 and $146,000 for 2ME2. The overall increase in research and development costs in the three-month and nine month periods ended September 30, 2013, as compared to same period in 2012, reflects increased costs associated with the clinical development of ENMD-2076 in the U.S. and China during 2013, as well as an increase in non-cash stock-based compensation expense, offset by lower patent costs and the absence of severance related costs in the 2013 period.
At September 30, 2013, accumulated direct project expenses for 2ME2 were $58,069,000 and, since acquired, accumulated direct project expenses for ENMD-2076 totaled $23,173,000. Our research and development expenses also include non-cash stock-based compensation totaling $587,000 for the nine months ended September 30, 2013 and $186,000 for the corresponding 2012 period. The increase in non-cash stock-based compensation expense is due an increase in the number of option awards during the current period compared to the previous year. The balance of our research and development expenditures includes facility costs and other departmental overhead, and expenditures related to the non-clinical support of our programs.
16

We expect the majority of our research and development expenses in 2013 to be devoted to the development of our ENMD-2076 program. We expect our ENMD-2076 expenses for the remainder of 2013 to increase based on the availability of additional financial resources from our 2013 Financing and our clinical development plan. We will continue to conduct research on ENMD-2076 in order to comply with stipulations made by the FDA, as well as to increase understanding of the mechanism of action and toxicity parameters of ENMD-2076 and its metabolites. Completion of clinical development may take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate.
We estimate that clinical trials of the type we generally conduct are typically completed over the following timelines:
Global FDA Trial:
ESTIMATED
COMPLETION
CLINICAL PHASE
PERIOD
Phase 1
1-2 Years
Phase 2
2-3 Years
Phase 3
2-4 Years
Local CFDA Trial:
ESTIMATED
COMPLETION
CLINICAL PHASE
PERIOD
Phase 1
1 Year
Phase 2
2 Years
Phase 3
2-3 Years
The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during the clinical trial protocol, including, among others, the following:
-
the number of patients that ultimately participate in the trial;
-
the duration of patient follow-up that seems appropriate in view of the results;
-
the number of clinical sites included in the trials; and
-
the length of time required to enroll suitable patient subjects.
We test our potential product candidates in numerous preclinical studies to identify indications for which they may be product candidates. We may conduct multiple clinical trials to cover a variety of indications for each product candidate. As we obtain results from trials, we may elect to discontinue clinical trials for certain indications in order to focus our resources on more promising indications.
Our proprietary product candidates have also not yet achieved regulatory approval, which is required before we can market them as therapeutic products. In order to proceed to subsequent clinical trial stages and to ultimately achieve regulatory approval, regulatory agencies must conclude that our clinical data establish safety and efficacy. Historically, the results from preclinical testing and early clinical trials have often not been predictive of results obtained in later clinical trials. A number of new drugs and biologics have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals.
17

Our business strategy includes being opportunistic with collaborative arrangements with third parties to complete the development and commercialization of our product candidates. In the event that third parties take over the clinical trial process for one of our product candidates, the estimated completion date would largely be under the control of that third party rather than us. We cannot forecast with any degree of certainty which proprietary products or indications, if any, will be subject to future collaborative arrangements, in whole or in part, and how such arrangements would affect our capital requirements.
As a result of the uncertainties discussed above, among others, we are unable to estimate the duration and completion costs of our research and development projects. Our inability to complete our research and development projects in a timely manner or our failure to enter into collaborative agreements, when appropriate, could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time to time in order to continue with our business strategy. There can be no assurance that we will be able to successfully access external sources of financing in the future. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.
Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with internal and contract preclinical testing and clinical trials of our product candidates, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Research and development expenses increased to $794,000 during the three months ended September 30, 2013 from $623,000 for the corresponding period in 2012. Research and development expenses increased to $2,137,000 during the nine months ended September 30, 2013 from $1,881,000 for the corresponding period in 2012. The fluctuations in research and development expenditures during the three and nine months ended September 30, 2013 were specifically impacted by the following:
-
Outside Services – In the three-month period ended September 30, 2013, we expended $6,000 on outside service activities versus $14,000 in the same 2012 period. For the nine-month period ended September 30, 2013 outside services are $40,000 compared to $36,000 for the same 2012 period. The decrease in 2013 as compared to 2012 for the three month period reflects costs associated with the translation of documents to Chinese for regulatory purposes in China during the 2012 period. The increase in the nine month period primarily reflects costs associated with new trials for the development of the ENMD-2076 during the 2013 period.
-
Clinical Trial Costs – Clinical trial costs, which include clinical site fees, monitoring costs and data management costs, increased to $352,000 in the three months ended September 30, 2013 from $58,000 in the three-month period ended September 30, 2012. Clinical trial costs for the nine-month period ended September 30, 2013 increased to $556,000 from $186,000 for the comparable 2012 period. The increase during the 2013 period relates to costs associated with enrolling patients in Phase 2 clinical trials for TNBC during the 2013 period and increased costs associated with clinical research organization costs related to our crossover bioavailability and food effect study of ENMD-2076 during the 2013 period.
18

-
Contract Manufacturing Costs – The costs of manufacturing the material used in clinical trials for our product candidates is reflected in contract manufacturing. These costs include bulk manufacturing, encapsulation and fill and finish services, product release costs and storage fees. Contract manufacturing costs for the three months ended September 30, 2013 decreased by $80,000 compared to the same period in 2012. For the nine-month period ended September 30, 2013, manufacturing costs increased to $159,000 from $156,000 for the comparable 2012 period. The variance for both periods primarily reflects the timing of manufacturing costs incurred in China related to manufacturing of ENMD-2076.
-
Personnel Costs – Personnel costs increased to $251,000 in the three-month period ended September 30, 2013 from $201,000 in the corresponding 2012 period. This variance is attributed to an increase in non-cash stock-based compensation expense totaling $28,000 during the 2013 period and increased salary and benefit costs associated with new employees in China during the 2013 period. For the nine-month period, personnel costs increased in 2013 to $1,006,000 from $858,000 for the corresponding 2012 period. This variance is attributed to an increase in non-cash stock-based compensation expense totaling $401,000 during the 2013 period and increased salary and benefit costs associated with new employees in China during the 2013 period, offset by severance expense of $290,000 in the 2012 period.
-
Also reflected in our 2013 research and development expenses for the three-month period ended September 30, 2013 are patent costs of $14,000 and facility and related expenses of $30,000. In the corresponding 2012 period, these expenses totaled $136,000 and $24,000, respectively. For the nine-month period ended September 30, 2013, patent costs were $57,000 and facility and related expenses were $69,000. In the corresponding 2012 period, these expenses totaled $389,000 and $47,000, respectively. The decrease in patent costs during the 2013 period reflects higher costs in 2012 associated with the execution of our intellectual property strategy, including maintaining our patent portfolio and expanding our patent protection internationally. The increase in expenses in facilities and related expenses in 2013 resulted from leased office space in China.
General and Administrative Expenses. General and administrative expenses include compensation and other expenses related to finance, business development and administrative personnel, professional services and facilities.
General and administrative expenses increased to $649,000 in the three-month period ended September 30, 2013 from $565,000 in the corresponding 2012 period. The increase in the third quarter of 2013 is primarily related to an increase in stock-based compensation expense of $84,000. For the nine-month period, general and administrative expenses increased in 2013 to $2,294,000 from $2,263,000 for the corresponding 2012 period. The increase in the 2013 period is primarily related to an increase of $407,000 related to non-cash stock-based compensation during the 2013 period due to an increase in stock option awards during the period, offset by the reduction in personnel costs of $232,000, a reduction in Board of Directors fees of $77,000, as well as lower professional fees of $70,000 compared to the 2012 period.
Interest Expense . Interest expense for nine month period ended September 30, 2012 was $10,041,000. All of the interest expense was non-cash interest (including $684,000 related to amortization of deferred financing costs; $2,156,000 related to amortization of debt discount; and $145,000 related to accrued interest on our Notes payable which was converted to shares of common stock on May 1, 2012). Also included as non-cash interest expense for the nine month period ended September 30, 2012 was $7,057,000, representing the value of the beneficial conversion feature associated with the Notes. There was no interest expense for the three months ended September 30, 2012 or for the three and nine-months ended September 30, 2013.
19

Dividends on Series A Convertible Preferred Stock . The Consolidated Statement of Operations for the nine months ended September 30, 2012 reflects accrued, but unpaid, dividends of $335,000, which relate to Series A Convertible Preferred Stock held by Celgene pursuant to a Securities Purchase Agreement dated December 31, 2002. Celgene, the holder of Series A Preferred Stock accumulated dividends at a rate of 6% and participated in dividends declared and paid on the common stock, if any. In connection with the stockholder approval of the 2012 Financing on April 30, 2012, Celgene waived all accrued dividends on the Series A Preferred Stock, and is no longer entitled to any liquidation preference on its shares. There are no outstanding shares of Series A Convertible Preferred Stock and the Series A class of preferred stock has been eliminated.
LIQUIDITY AND CAPITAL RESOURCES
To date, we have been engaged primarily in research and development activities. As a result, we have incurred and expect to continue to incur operating losses in 2013 and the foreseeable future before we commercialize any products. Based on our current plans, we expect our current available cash and cash equivalents to meet our cash requirements for at least the next twelve months.
We will require significant additional funding to fund operations until such time, if ever, we become profitable. We intend to augment our cash balances by pursuing other forms of capital infusion, including strategic alliances or collaborative development opportunities with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of our potential product candidates that we intend to pursue to commercialization. If we seek strategic alliances, licenses, or other alternative arrangements, such as arrangements with collaborative partners or others, to raise further financing, we may need to relinquish rights to certain of our existing product candidates, or products we would otherwise seek to develop or commercialize on our own, or to license the rights to our product candidates on terms that are not favorable to us.
We will continue to seek to raise additional capital to fund our research and development and advance the clinical development of ENMD-2076 and new product candidates, if any. We intend to explore one or more of the following alternatives to raise additional capital:
·
selling additional equity securities;
·
out-licensing product candidates to one or more corporate partners;
·
completing an outright sale of non-priority assets; and/or
·
engaging in one or more strategic transactions.
We also will continue to manage our cash resources prudently and cost-effectively.
There can be no assurance that adequate additional financing under such arrangements will be available to us on terms that we deem acceptable, if at all. If additional funds are raised by issuing equity securities, dilution to existing shareholders may result, or the equity securities may have rights, preferences, or privileges senior to those of the holders of our common stock. If we fail to obtain additional capital when needed, we may be required to delay or scale back our Phase 2 plans for ENMD-2076 or plans for other product candidates, if any.
At September 30, 2013, we had cash of $15,871,694, with working capital of $15,686,346.
20

INFLATION AND INTEREST RATE CHANGES
Management does not believe that our working capital needs are sensitive to inflation and changes in interest rates.
ITEM 3.       QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The primary objective of our investment activities is to preserve our capital until it is required to fund operations while at the same time maximizing the income we receive from our investments without incurring investment market volatility risk. Our investment income is sensitive to the general level of U.S. interest rates. In this regard, changes in the U.S. interest rates affect the interest earned on our cash and cash equivalents. Due to the short-term nature of our cash and cash equivalent holdings, a 10% movement in market interest rates would not materially impact on the total fair market value of our portfolio as of September 30, 2013.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Chief Executive Officer and Principal Accounting Officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) were effective as of September 30, 2013 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its Chief Executive Officer and Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosure.
Management’s assessment of the effectiveness of internal control over financial reporting is expressed at the level of reasonable assurance because a control system, no matter how well designed and operated, can provide only reasonable, but not absolute, assurance that the control system’s objectives will be met.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal control over financial reporting that occurred during the quarter ended September 30, 2013 that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.
21

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, except as otherwise disclosed herein, are material.
ITEM 1A. RISK FACTORS
For information regarding factors that could affect the Company’s results of operations, financial condition and liquidity, see the risk factors discussion set forth in Item 1A of EntreMed’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and the information under “Special Note Regarding Forward-Looking Statements” included in this report. There have been no material changes to our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. REMOVED AND RESERVED
ITEM 5. OTHER INFORMATION
Not applicable.
ITEM 6. EXHIBITS
31.1
Rule 13a-14(a) Certification of Chief Executive Officer
31.2
Rule 13a-14(a) Certification of Principal Accounting Officer
32.1
Section 1350 Certification of Chief Executive Officer
32.2
Section 1350 Certification of Principal Accounting Officer
101
The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Consolidated Balance Sheets at September 30, 2013 and December 31, 2012, (ii) Unaudited Consolidated Statements of Operations for the Three and Nine months ended September 30, 2013 and 2012, (iii) Unaudited Consolidated Statements of Cash Flows for the Nine months ended September 30, 2013 and 2012 and (iv) Notes to Unaudited Consolidated Financial Statements.*
* This exhibit is furnished and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (15 U.S.C. 78r), or otherwise subject to the liability of that section. Such exhibit will not be deemed to be incorporated by reference into any filing under the Securities Act or Securities Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.
22

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ENTREMED, INC.
(Registrant)
Date: November 14, 2013
/s/ Ken K. Ren
Ken K. Ren
Chief Executive Officer
Date: November 14, 2013
/s/ Sara B. Capitelli
Sara B. Capitelli
Principal Accounting Officer
23

EXHIBIT INDEX
31.1
Rule 13a-14(a) Certification of Chief Executive Officer
31.2
Rule 13a-14(a) Certification of Principal Accounting Officer
32.1
Section 1350 Certification of Chief Executive Officer
32.2
Section 1350 Certification of Principal Accounting Officer
101
The following financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, formatted in eXtensible Business Reporting Language (XBRL): (i) Unaudited Consolidated Balance Sheets at September 30, 2013 and December 31, 2012, (ii) Unaudited Consolidated Statements of Operations for the Three and Nine months ended September 30, 2013 and 2012, (iii) Unaudited Consolidated Statements of Cash Flows for the Nine months ended September 30, 2013 and 2012 and (iv) Notes to Unaudited Consolidated Financial Statements.*
* This exhibit is furnished and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (15 U.S.C. 78r), or otherwise subject to the liability of that section. Such exhibit will not be deemed to be incorporated by reference into any filing under the Securities Act or Securities Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.
24

TABLE OF CONTENTS